Sorrento Therapeutics Inc

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. The Sorrento Therapeutics segment consists of developing a portfolio of next generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. The Scilex segment is largely organized around the company's non-opioid pain management operations. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

The company does appear to be stretched. But there are still advantages for SRNE stock that make it interesting to investors.

While Risky, Sorrento Therapeutics Has Many Options to Win

If you want to wager on a company with a multi-pronged approach to treating the Covid-19 virus, look no further than SRNE stock. The post Get Aggressive in the Anti-Covid Fight with Sorrento Therapeutics Stock appeared first on InvestorPlace.

Get Aggressive in the Anti-Covid Fight with Sorrento Therapeutics Stock

VBI Vaccines

Vaxart

Here's why investors should stay away from some of the riskiest coronavirus stocks on the market.

Beware of Investing in These 3 Small-Cap Coronavirus Stocks

There are several established biotech companies for investors to consider but they should avoid buying SRNE stock. The post Sorrento Therapeutics Isn't the Way to Play Covid Stocks appeared first on InvestorPlace.

Sorrento Therapeutics Isn't the Way to Play Covid Stocks

Will the lack of focus be the biotech's downfall?

Tests, Treatments, Vaccines: Sorrento Therapeutics Is All In on COVID-19

Moderna

Both biotechs have promising COVID-19 programs. But one is a much better pick at this point.

Better Coronavirus Stock: Moderna vs. Sorrento Therapeutics

The loss-making company is opening its wallet for a complementary new asset.

Why Sorrento Therapeutics Stock Cratered on Friday

The American biotech aims to recruit 400 people for the study.

Brazil Healthcare Regulator Authorizes Sorrento Therapeutics' Phase 2 Trial for Coronavirus Drug Candidate

While Sorrento Therapeutics has an impressive pipeline, it needs to bring something to market. The clock is ticking on SRNE stock.

Don’t Give Up on Sorrento Therapeutics Stock Just Yet

With the novel coronavirus becoming an extended reality for us, no one platform offers a comprehensive solution. And that’s why Sorrento Therapeutics’ all-in pivot bodes well for SRNE stock.

3 Reasons to Inject Your Portfolio with Sorrento Therapeutics

The biotech's COVID-19 pipeline update isn't sitting well with shareholders today.

Why Sorrento Therapeutics Is Tanking Today

SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase 2 clinical trial of Abivertinib in mild, moderate and severe COVID-19 patients.

Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients

The company's pipeline is large. Its list of FDA-authorized drugs is nonexistent.

Sorrento Therapeutics Adds Another COVID-19 Treatment to Its Pipeline

SAN DIEGO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has entered into an exclusive license agreement with Personalized Stem Cells, Inc. (PSC) to acquire global rights to its adipose derived mesenchymal stem cells (MSCs) for patients suffering from acute respiratory distress syndrome (ARDS) associated with COVID-19, which have been cleared for a Phase 1 clinical trial by the FDA.

Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COVID-19 Focused Rescue Therapies

Sorrento has a ton of interesting clinical work going on. But with Covid-19 science rapidly advancing, SRNE stock doesn't have much time left to cash in.

Sorrento Stock Needs to Show Results

SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today released details about its upcoming COVID-19 Pipeline Update call and webcast on October 13th, 2020.

Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released

Sorrento Therapeutics (SRNE) closed the most recent trading day at $11.29, moving +0.98% from the previous trading session.

Sorrento Therapeutics (SRNE) Outpaces Stock Market Gains: What You Should Know

SRNE stock buyers beware. Company management has long targeted unsuspecting biotech investors in never-ending game of fundraising.

Sorrento Stock Investors Should Play Powerball Instead

While SRNE stock carries a lot of risk, the potential reward from one of its coronavirus plays panning out makes it attractive among biotech stocks. The post The Risk Is Worth the Reward for Sorrento Stock appeared first on InvestorPlace.

The Risk Is Worth the Reward for Sorrento Stock

Sorrento Therapeutics shareholders witnessed SRNE stock gain 70% in the past month. The risk-to-reward proposition has gone from good to bad.

The Risk-to-Reward Proposition for Sorrento Has Gone Bad

SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has discovered a small molecule termed Salicyn-30 that demonstrated a potent 3-4 log reduction of SARS-CoV-2 virus infection in an in vitro virus infection experiment.

Sorrento Announces the Discovery of Salicyn-30 Small Molecule That Strongly Inhibits SARS-CoV-2 Infection in Preclinical Studies and Highlights its Place in a Potential Multi-Modal Therapy Strategy in Combination With Neutralizing Antibodies Against COVID

If you love to gamble, SRNE stock is the right one for you. Few other companies, if any, have pivoted as hard as Sorrento did toward Covid-19.

Does Sorrento Therapeutics Meet the ‘SAD’ Criteria for Vaccines?

Sorrento's stock outperformed the broader biotech industry by a wide margin last month.

Why Sorrento Therapeutics Stock Bolted Higher in September

PALO ALTO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), today announced continuous sales growth in ZTlido® from quarter to quarter in 2020. Scilex expects third quarter 2020 ZTlido® net sales to grow 26% to approximately $7.2MM, compared to $5.7MM in Q2-2020. The preliminary third quarter 2020 net sales information presented in this press release is based on Scilex’s current expectations and may be adjusted as a result of, among other things, completion of customary quarterly review procedures.

Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020

SAN DIEGO, Oct. 04, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced it will host a R&D Day conference call and simultaneous webcast on October 13th, 2020 focusing on its comprehensive multi-modal approach to COVID-19.

News for Sorrento Therapeutics Inc Stock (SRNE)